
Jung Hyun Jo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3660678/publications.pdf Version: 2024-02-01



Ιυνό Ηγμνιο

#	Article	IF	CITATIONS
1	Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Gut and Liver, 2022, 16, 118-128.	1.4	7
2	Minimal and Maximal Extent of Band Ligation for Acute Variceal Bleeding during the First Endoscopic Session. Gut and Liver, 2022, 16, 101-110.	1.4	1
3	BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Cancers, 2022, 14, 236.	1.7	6
4	Revised Clinical Practice Guideline of Korean Pancreatobiliary Association for Acute Pancreatitis: Severity Assessment. The Korean Journal of Pancreas and Biliary Tract, 2022, 27, 12-21.	0.0	0
5	Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Cancers, 2022, 14, 1244.	1.7	0
6	A phase I/ <scp>II</scp> study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. International Journal of Cancer, 2022, 151, 1565-1577.	2.3	8
7	Efficacy and safety of palliative endobiliary radiofrequency ablation using a novel temperature-controlled catheter for malignant biliary stricture: a single-center prospective randomized phase II TRIAL. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 63-73.	1.3	36
8	Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 516-522.	1.4	22
9	Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. EBioMedicine, 2021, 65, 103218.	2.7	5
10	Optimal drainage of anastomosis stricture after living donor liver transplantation. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 6307-6317.	1.3	1
11	KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma Journal of Clinical Oncology, 2021, 39, 4020-4020.	0.8	2
12	Abstract CT171: Combinatorial allogeneic NK cell therapy with Pembrolizumab for cholangiocarcinoma; interim report of open label Phase1/2a study. , 2021, , .		2
13	Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. JMIR MHealth and UHealth, 2021, 9, e21088.	1.8	15
14	GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, 1241.	1.1	7
15	Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 499-507.	1.4	10
16	Comparative efficacy of stents in endoscopic ultrasonographyâ€guided peripancreatic fluid collection drainage: A systematic review and network metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 941-952.	1.4	13
17	Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing block of clinical T staging?. Pancreatology, 2020, 20, 952-959.	0.5	2
18	Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 651-659.	1.1	8

Jung Hyun Jo

#	Article	IF	CITATIONS
19	FOLFIRINOX <i>vs</i> gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World Journal of Gastrointestinal Oncology, 2020, 12, 182-194.	0.8	40
20	A novel lumen-apposing metal stent with an anti-reflux valve for endoscopic ultrasound-guided drainage of pseudocysts and walled-off necrosis: A pilot study. PLoS ONE, 2019, 14, e0221812.	1.1	10
21	Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs. BMC Medical Genomics, 2019, 12, 62.	0.7	19
22	Novel Gastric Cancer Stem Cell-Related Marker LINGO2 Is Associated with Cancer Cell Phenotype and Patient Outcome. International Journal of Molecular Sciences, 2019, 20, 555.	1.8	24
23	Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 662-669.	0.5	9
24	KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 62-66.	0.6	2
25	Sameâ€session endoscopic ultrasoundâ€guided fine needle aspiration and endoscopic retrograde cholangiopancreatographyâ€based tissue sampling in suspected malignant biliary obstruction: A multicenter experience. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 799-805.	1.4	32
26	Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 375-379.	1.4	5
27	Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 421-430.	0.8	25
28	Best options for preoperative biliary drainage in patients with Klatskin tumors. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 422-429.	1.3	41
29	Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer. Chemotherapy, 2017, 62, 361-366.	0.8	8
30	Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean―population: A single-center cohort study. Seminars in Oncology, 2017, 44, 420-427.	0.8	16
31	Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma. World Journal of Gastroenterology, 2017, 23, 3301.	1.4	40
32	Clinical characteristics of second primary pancreatic cancer. PLoS ONE, 2017, 12, e0179784.	1.1	15
33	Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer. Pancreas, 2014, 43, 1022-1031.	0.5	10
34	Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer, 2014, 17, 703-710.	2.7	100
35	Gastrojejunostomy by pure natural orifice transluminal endoscopic surgery using a newly designed anastomosing metal stent in a porcine model. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1439-1446.	1.3	12
36	High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case–control study. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 4210-4216.	1.3	13

Jung Hyun Jo

#	Article	IF	CITATIONS
37	Transition zone defect associated with the response to proton pump inhibitor treatment in patients with globus sensation. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 954-962.	1.4	5
38	A Case of Actinomycosis in a Patient Treated with Chemotherapy Due to Recurrent Pancreatic Cancer. Korean Journal of Medicine, 2013, 85, 401.	0.1	1
39	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. Digestion, 2012, 86, 264-272.	1.2	2
40	VIPoma that arose from the rectum in a 65-year-old male patient. International Journal of Colorectal Disease, 2012, 27, 1385-1386.	1.0	3